Grape Seed Extract VS Low Level Laser Therapy for Dentin Hypersensitivity

Sponsor
Manipal University College Malaysia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05927831
Collaborator
(none)
30
1
3
8
3.7

Study Details

Study Description

Brief Summary

Dentin hypersensitivity (DH) is a common clinical problem frequently seen in dental patients. According to Splieth et al., the prevalence of dentin hypersensitivity is 3-98% in adult population.DH is described as a short, sharp pain or discomfort that responses to certain stimuli, typically thermal, tactile, osmotic or chemical, due to exposed dentinal surface which can be explained by the hydrodynamic theory.

The laser is a narrow, focused beam of light emitted to vaporise, fuse, melt, or seal dentinal tubules using laser heat to induce hydroxyapatite crystals for recrystallisation of the mineral component of dentine. The obliteration of dentinal tubules is caused by heat generated by laser beam which inhibits the transmission of the stimulus in the dentinal tubules.

Grape seed extract contains proanthocyanidins (PA) which is able to bind to proline-rich proteins, like collagen, and contributes in enzyme proline hydroxylase activity that is essential for the biosynthesis of collagen in the dentin. The cross-linking action of collagen fibrils in dentin also able to prevent mineral loss.

Condition or Disease Intervention/Treatment Phase
  • Drug: Grape Seed Extract
  • Device: Low-level laser therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of the Effectiveness of Grape Seed Extract (GSE) and Low-level Laser Therapy in the Management of Dentin Hypersensitivity: A Randomized Control Trial
Actual Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
Jan 15, 2024
Anticipated Study Completion Date :
Jan 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Grape seed extract

grape seed extract with 95% proanthocyanins will be applied topically to the hypersensitive dentin area for 10 minutes, followed by rinsing with water.

Drug: Grape Seed Extract
Grape seed extract will be applied in the form of a gel on the tooth surface
Other Names:
  • GSE
  • Experimental: Low-level laser therapy

    The low-level laser diode treatment of 810 nm will be performed using a commercially available diode laser device. The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode starting at a distance of 5-6 mm away from the hypersensitive tooth area and slowly approaching within a distance of 2-3mm in a scanning motion covering the entire hypersensitive tooth area for a period of 30 seconds to 1 minute.

    Device: Low-level laser therapy
    The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode

    Experimental: Combination of low-level laser therapy and grape seed extract

    Grape seed extract will be applied topically to the hypersensitive dentin area for 10 minutes, followed by low-level laser diode treatment.

    Drug: Grape Seed Extract
    Grape seed extract will be applied in the form of a gel on the tooth surface
    Other Names:
  • GSE
  • Device: Low-level laser therapy
    The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode

    Outcome Measures

    Primary Outcome Measures

    1. The patients' dentin hypersensitivity levels will be measured using a visual analogue scale (VAS) [1st day]

      The patients' dentin hypersensitivity levels will be measured using a visual analogue scale (VAS)(0 to 10) before and after treatment.

    2. The patients' dentin hypersensitivity levels will be measured using a visual analogue scale (VAS) [3rd day]

      The patients' dentin hypersensitivity levels will be measured using a visual analogue scale (VAS)(0 to 10) after treatment.

    3. The patients' dentin hypersensitivity levels will be measured using a visual analogue scale (VAS) [7th day]

      The patients' dentin hypersensitivity levels will be measured using a visual analogue scale (VAS)(0 to 10) after treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with at least three sensitive tooth by gingival recession or tooth wear >2 scores on the VAS scale.

    • Tooth wear index score <3 (Smith and Knight tooth wear index)

    • Systemically healthy patient.

    • 20-50 years of age.

    Exclusion Criteria:
    • Teeth with caries, cracked teeth, mobile teeth and pulpitis.

    • Deep periodontal pockets (probing depth >6 mm), periodontal surgery within the previous 3 months.

    • Recent desensitizing therapy

    • systemic diseases and gastric diseases (GERD)

    • Allergy to active ingredients.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Manipal University College Malaysia Melaka Tengah Melaka Malaysia 75450

    Sponsors and Collaborators

    • Manipal University College Malaysia

    Investigators

    • Principal Investigator: Tun Yi Darren Ong, Manipal University College Malaysia
    • Principal Investigator: Li Jia Ong, Manipal University College Malaysia
    • Principal Investigator: Ju Wen Lim, Manipal University College Malaysia
    • Principal Investigator: Wei Nee Lim, Manipal University College Malaysia
    • Principal Investigator: Gursimrendeep Kaur, Manipal University College Malaysia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Anchu Rachel Thomas, Associate Professor Dr., Manipal University College Malaysia
    ClinicalTrials.gov Identifier:
    NCT05927831
    Other Study ID Numbers:
    • 018/2023
    First Posted:
    Jul 3, 2023
    Last Update Posted:
    Jul 3, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 3, 2023